Genfit (GNFT) Q3 2025 TU earnings summary

Executive summary

• Cash and cash equivalents reached €119.0 million as of September 30, 2025, up from €107.5 million at June 30, 2025, and €81.8 million at December 31, 2024.

• Revenue for the first nine months of 2025 was €39.2 million, primarily from milestone and royalty payments related to IqirvoⓇ (elafibranor).

• IqirvoⓇ (elafibranor) continues to show solid growth in both U.S. and European markets for PBC.

Financial highlights

• €26.5 million milestone payment received in July 2025 after pricing and reimbursement approval of IqirvoⓇ in the UK, Germany, and Italy.

• Royalty revenue from worldwide sales of IqirvoⓇ (excluding Greater China) totaled €12.6 million in the first nine months of 2025.

• Revenue for the first nine months of 2025 decreased to €39.2 million from €59.7 million in the same period of 2024.

Outlook and guidance

• Existing cash and cash equivalents are expected to fund operations and capital expenditures beyond the end of 2028, assuming continued milestone and royalty payments.

• Future commercial milestone revenue is anticipated from the Ipsen license agreement, contingent on sales-based thresholds.

• Additional payments of up to €55 million may be received under the royalty financing agreement with HCRx, subject to achieving objectives.